The pharmaceutical industry is poised for a potential blockbuster year in 2025, with analysts at Evaluate forecasting that the top 10 most anticipated drug launches could generate a combined $29 billion in annual sales by 2030. This impressive figure nearly doubles the previous year’s forecast of $15.2 billion, marking the highest projected total in five years.
- Alyftrek (Vertex Pharmaceuticals) Leading the pack is Vertex’s newly approved cystic fibrosis treatment, Alyftrek (vanza triple). Approved in December 2024, this once-daily triple combination therapy is projected to reach $8.3 billion in sales by 2030. The drug improves upon its predecessor Trikafta and extends treatment to 31 additional mutations, potentially helping 150 new CF patients in the U.S. become eligible for treatment.
- Datroway (Daiichi Sankyo/AstraZeneca) Recently approved in January 2025, this antibody-drug conjugate for lung and breast cancers is expected to generate $5.9 billion in sales by 2030. While the drug faced some setbacks in previous trials, it secured its first FDA approval for HR-positive, HER2-negative breast cancer and is pursuing additional indications.
- Suzetrigine (Vertex Pharmaceuticals) This non-opioid pain medication could become the first novel pain mechanism approved in decades. With projected 2030 sales of $2.9 billion, suzetrigine is currently under FDA priority review for moderate to severe acute pain, with a decision expected by January 30, 2025.
- Aficamten (Cytokinetics) This cardiac myosin inhibitor for hypertrophic cardiomyopathy is anticipated to generate $2.8 billion in sales by 2030. Cytokinetics plans to commercialize the drug independently in the U.S. and Europe, with an FDA decision expected by late September.
- Brensocatib (Insmed) Expected to be the first approved treatment for non-cystic fibrosis bronchiectasis, this drug could reach $2.8 billion in sales by 2030. Insmed is anticipating a potential launch in the third quarter of 2025, pending FDA approval.
- Tolebrutinib (Sanofi) This BTK inhibitor for multiple sclerosis has overcome several challenges to become the first in its class to receive FDA breakthrough therapy designation. Analysts project 2030 sales of $1.4 billion.
- Mazdutide (Innovent/Eli Lilly) This dual GLP-1/glucagon receptor agonist for type 2 diabetes and obesity is expected to generate $1.3 billion in sales by 2030. It could become the first drug of its kind approved for these indications.
- Depemokimab (GSK) GSK’s long-acting monoclonal antibody for severe allergic asthma, requiring dosing only every six months, is projected to reach $1.2 billion in sales by 2030. The extended dosing schedule could provide a significant advantage over existing treatments.
- MenABCWY Vaccine (GSK) This five-in-one meningococcal vaccine combines protection against strains A, B, C, W-135, and Y. With an FDA decision expected by February 14, 2025, it’s projected to achieve $1.2 billion in sales by 2030.
- Nipocalimab (Johnson & Johnson) J&J’s antibody treatment for myasthenia gravis and other autoimmune disorders rounds out the list with projected 2030 sales of $1.2 billion. The drug is under FDA priority review and could potentially receive approval for a broader patient population than existing treatments.
This impressive lineup of potential blockbuster drugs spans multiple therapeutic areas, from rare diseases to chronic conditions, and represents significant advances in treatment options for patients. The success of these launches could reshape the pharmaceutical landscape and provide important new therapeutic options for patients across multiple disease areas.
